Bristol Myers Squibb

BioMarin Adds Bristol Myers Squibb Research Chief Robert Plenge to Board

San Rafael, Calif. – September 17, 2026 -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) has appointed Robert Plenge, M.D., Ph.D., to its Board of Directors, effective September 10, 2026.

Plenge brings nine-site global research oversight from Bristol Myers Squibb

Dr. Plenge currently serves as Executive Vice President, Chief Research Officer and Head of Research at Bristol Myers Squibb, directing scientific operations across nine research sites worldwide. He joined the company in November 2019 through its acquisition of Celgene Corp., where he had led the immunology and inflammation portfolio in research and early development.

SystImmune's Iza-bren Hits Phase 3 Dose in Global Lung Cancer Trial

Seoul – September 12, 2026 -- SystImmune, Inc. announced that new global Phase 1 data support 2.5 mg/kg D1D8 Q3W as the recommended Phase 3 dose for iza-bren (izalontamab brengitecan), a bispecific EGFRxHER3 antibody drug conjugate, in previously treated EGFR-mutated metastatic non-small cell lung cancer (NSCLC).

Randomized Phase 1 cohort confirms higher efficacy at the 2.5 mg/kg dose level

The abstract, presented in an oral session at the IASLC 2026 World Conference on Lung Cancer (WCLC) in Seoul, South Korea, evaluated iza-bren across three dose levels in a randomized dose-expansion cohort. Patients enrolled had EGFR-mutated metastatic NSCLC and had previously received a third-generation EGFR inhibitor. Results showed promising antitumor activity with a manageable safety profile, with the highest efficacy observed at the 2.5 mg/kg dose.

CD&R Names Ex-BMS CEO Giovanni Caforio Operating Advisor

London – September 9, 2026 -- CD&R has appointed Giovanni Caforio, current Chair of Novartis and former CEO of Bristol Myers Squibb (BMS), as an Operating Advisor to its funds, tasking him with sourcing and evaluating healthcare investment opportunities globally.

Caforio brings 35 years of biopharmaceutical leadership to CD&R's healthcare strategy

Dr. Caforio has led Novartis' board since 2025 and previously spent over two decades at BMS after 12 years at Abbott Laboratories. He will support CD&R funds in identifying new healthcare deals and work directly with the firm's portfolio companies worldwide.

INBI Launches in Israel, Names Anat Cohen-Dayag CEO of Core Unit

Tel Aviv – – September 11, 2026 -- The Israel National Biotech Innovation Center (INBI) officially launched operations, uniting 15 of Israel's top universities, research institutions and healthcare organizations under a single translational platform for the first time.

Anat Cohen-Dayag Takes Helm of INBI Core

Anat Cohen-Dayag, PhD, Executive Chairperson of Compugen and formerly its President and CEO for 15 years, has been appointed Chief Executive Officer of INBI Core Ltd., the wholly owned operational subsidiary of INBI. Samuel Moed, former Senior Vice President of Corporate Strategy at Bristol Myers Squibb, will chair both INBI and INBI Core.